TABLE 3. Among gay, bisexual, and other men who have sex with men with diagnosed HIV infection, percentage with antiretroviral therapy adherence, percentage with viral suppression, and median HIV-related stigma scores, by race/ethnicity and age group — United States, 2018 and 2019.
| Characteristic | ART adherence (2018)* |
Viral suppression (2019)† |
HIV-related stigma score (2018)§ |
|||
|---|---|---|---|---|---|---|
| No. | % (95% CI) | No. | % | No. | Median (95% CI) | |
|
Total
|
1,869 |
58.3 (54.9–61.7) |
528,606 |
68.1 |
1,873 |
29.3 (28.0–30.5) |
|
Race/Ethnicity
| ||||||
| American Indian/Alaska Native |
—¶ |
—¶ |
1,538 |
64.7 |
—¶ |
—¶ |
| Asian |
—¶ |
—¶ |
9,779 |
71.7 |
—¶ |
—¶ |
| Black/African American |
503 |
48.3 (40.2–56.3) |
161,072 |
61.6 |
528 |
32.8 (29.3–36.3) |
| Hispanic/Latino** |
440 |
58.7 (53.4–64.1) |
135,301 |
66.6 |
436 |
32.0 (29.6–34.3) |
| Native Hawaiian/Other Pacific Islander |
—¶ |
—¶ |
590 |
66.2 |
—¶ |
—¶ |
| White |
784 |
64.1 (59.4–68.9) |
195,335 |
73.5 |
770 |
26.1 (24.0–28.2) |
| Multiple races†† |
104 |
55.7 (44.8–66.7) |
24,643 |
74.5 |
103 |
30.4 (24.2–36.6) |
| American Indian/Alaska Native, Asian, or Native Hawaiian/Other Pacific Islander§§ |
38 |
60.2¶¶ (40.2–80.2) |
—§§ |
—§§ |
36 |
20.3 (12.0–28.7) |
|
Age group, yrs
| ||||||
| 13–24 |
—*** |
—*** |
19,520 |
66.2 |
—*** |
—*** |
| 18–24 |
53 |
44.6¶¶ (29.5–59.6) |
—*** |
—*** |
56 |
39.3 (30.0–48.7) |
| 25–34 |
319 |
47.7 (39.7–55.7) |
105,957 |
65.0 |
332 |
33.6 (30.6–36.6) |
| 35–44 |
346 |
53.7 (47.5–59.9) |
101,620 |
66.1 |
353 |
31.5 (29.7–33.4) |
| 45–54 |
523 |
55.7 (50.3–61.1) |
140,157 |
69.3 |
517 |
28.7 (26.8–30.6) |
| ≥55 | 628 | 69.6 (64.9–74.4) | 161,352 | 70.6 | 615 | 25.4 (23.5–27.3) |
Abbreviations: ART = antiretroviral therapy; MSM = men who have sex with men; NHBS = National HIV Behavioral Surveillance; PrEP = preexposure prophylaxis.
* Based on data collected by the Medical Monitoring Project during June 2018–May 2019. ART adherence was defined as taking 100% of ART doses in the past 30 days among MSM currently taking ART.
† Based on data reported through December 2020 to the National HIV Surveillance System for year-end 2019. Viral suppression was defined as the number of MSM with a viral load test result of <200 copies of HIV RNA per mL at last test divided by the number of MSM with diagnosed HIV infection.
§ Based on data collected by the Medical Monitoring Project during June 2018–May 2019. HIV-related stigma was measured using a 10-item scale that measures four dimensions of HIV stigma: personalized stigma during the past 12 months, current disclosure concerns, current negative self-image, and current perceived public attitudes about persons with HIV. The stigma score ranged from 0 to 100, with 0 indicating no stigma and 100 indicating highest stigma. A median score was calculated based on responses on a five-point Likert scale to each item. Median scores with nonoverlapping 95% CIs were considered to be meaningfully different. Median scores were interpreted in the context of the national goal of reducing HIV-related stigma by 2025 by at least 50% from the 2018 baseline median score of 31.
¶ Estimates are not available because denominator sample sizes are <30.
** Hispanic/Latino MSM could be any race.
†† Represents persons identified as having multiple race categories selected.
§§ Viral suppression percentages are presented separately for American Indian or Alaska Native persons, Asian persons, and Native Hawaiian or Other Pacific Islander persons.
¶¶ Estimates have a CI width >30 and should be interpreted with caution.
*** The Medical Monitoring Project did not collect data from persons aged 13–17 years. Data from the National HIV Surveillance System are presented for persons aged 13–24 years.